Price T Rowe Associates Inc. MD Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Price T Rowe Associates Inc. MD trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 92,166 shares of the biotechnology company’s stock after selling 3,824 shares during the period. Price T Rowe Associates Inc. MD’s holdings in BioCryst Pharmaceuticals were worth $1,457,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. FMR LLC boosted its position in BioCryst Pharmaceuticals by 15.9% during the first quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after buying an additional 475,989 shares during the period. Artisan Partners Limited Partnership boosted its position in BioCryst Pharmaceuticals by 3.9% during the second quarter. Artisan Partners Limited Partnership now owns 3,143,485 shares of the biotechnology company’s stock valued at $49,699,000 after buying an additional 117,879 shares during the period. Geode Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 4.1% during the second quarter. Geode Capital Management LLC now owns 3,112,562 shares of the biotechnology company’s stock valued at $49,209,000 after buying an additional 122,039 shares during the period. Nuveen Asset Management LLC boosted its position in BioCryst Pharmaceuticals by 2.4% during the second quarter. Nuveen Asset Management LLC now owns 2,565,420 shares of the biotechnology company’s stock valued at $40,559,000 after buying an additional 61,065 shares during the period. Finally, Northern Trust Corp boosted its position in BioCryst Pharmaceuticals by 26.0% during the second quarter. Northern Trust Corp now owns 2,460,312 shares of the biotechnology company’s stock valued at $38,897,000 after buying an additional 508,184 shares during the period. Institutional investors and hedge funds own 58.53% of the company’s stock.

Several analysts have issued reports on BCRX shares. JMP Securities restated a “buy” rating and set a $23.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, September 16th. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 3rd. They set an “overweight” rating and a $21.00 target price for the company. Piper Sandler increased their target price on shares of BioCryst Pharmaceuticals from $18.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, August 5th. Royal Bank of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating for the company in a report on Thursday, November 4th. Finally, Barclays dropped their target price on shares of BioCryst Pharmaceuticals from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 4th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Buy” and a consensus target price of $20.20.

BCRX stock opened at $12.50 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.59 and a 1 year high of $18.48. The company has a market cap of $2.24 billion, a P/E ratio of -9.84 and a beta of 2.51. The firm has a 50-day moving average of $13.98 and a 200 day moving average of $15.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). BioCryst Pharmaceuticals had a negative return on equity of 5,272.40% and a negative net margin of 198.88%. The company had revenue of $40.99 million during the quarter, compared to the consensus estimate of $37.75 million. During the same period in the previous year, the company earned ($0.26) earnings per share. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -1.26 earnings per share for the current year.

In other BioCryst Pharmaceuticals news, CFO Anthony Doyle bought 35,258 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was acquired at an average price of $12.48 per share, with a total value of $440,019.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vincent Milano bought 7,500 shares of the firm’s stock in a transaction on Wednesday, November 24th. The shares were acquired at an average cost of $12.19 per share, with a total value of $91,425.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 184,000 shares of company stock valued at $2,795,010. 4.80% of the stock is owned by insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.

Featured Story: Dual Listing

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.